SCHEMBL2708239

SCHEMBL2708239

CC(Oc1cccc(C(=O)O)c1)c1cccc(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA6 P23280 1/20 0.54
CA9 Q16790 1/20 0.54
AKR1C3 P42330 1/20 0.49
NR4A2 P43354 4/20 0.47
KMT2A Q03164 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.46
PPARA Q07869 1/20 0.45
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
FOLH1 Q04609 1/20 0.44
LMNA P02545 1/20 0.43
HIF1A Q16665 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NR4A1 P22736 1/20 0.43
NR4A3 Q92570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14968991 0.86 AKR1C3 (0.53) AKR1C3NR4A2KMT2AMRGPRX4PPARA
SCHEMBL8765671 0.81 FFAR1 (0.49) LMNAHIF1AKDM4E
SCHEMBL8791775 0.81 NR4A2 (0.49) AKR1C3NR4A2KMT2AMRGPRX4PPARA
SCHEMBL30184304 0.77 RXRA (0.68) AKR1C3NR4A2KMT2ARXRARXRB
SCHEMBL592781 0.77 RXRA (0.68) AKR1C3NR4A2KMT2ARXRARXRB
SCHEMBL2878702 0.77 AKR1C3 (0.61) CA12CA1CA2CA6CA9
SCHEMBL1499155 0.76 AKR1C3 (0.76) CA12CA1CA2CA6CA9
SCHEMBL8517905 0.76 AKR1C3 (0.59) CA12CA1CA2CA6CA9
SCHEMBL6623075 0.75 AKR1C3 (0.54) AKR1C3NR4A2KMT2AMRGPRX4RXRA
SCHEMBL9005549 0.74 SRD5A2 (0.63) CA12CA1CA2CA6CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450494-B2 Disubstituted benzamide derivatives as glucokinase (GK) activators CADILA HEALTHCARE LIMITED (IN) 2013-05-28 US disclosed
US-20120149704-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2012-06-14 US disclosed
EP-2445908-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS Cadila Healthcare Limited (IN) 2012-05-02 EP disclosed
WO-2010150280-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149704-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS GCKR, GCK, GK CA12 3288/4885CA1 3807/4885CA2 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.